Posts in category Long Ideas


GW Pharmaceuticals (GWPH): Epidiolex Will Be Approved Much Before the PDUFA Date, Bets Cantor

Cantor’s Elemer Piros now expects 52% in return potential for GWPH stock and sets a 100% probability of success for Epidiolex.

Red Hat Inc (RHT) Fires “On All Cylinders” in FQ4 Earnings Show, Draws Price Target Lift

After a stellar FQ4 earnings show from RHT, Christopher Eberle now calls for 14% in return potential for the stock.

HTG Molecular Diagnostics Inc (HTGM) Wins Over a Price Target Lift; Here’s Why

Canaccord’s Mark Massaro now bets on 50% in return potential for the healthcare player.

Marinus Pharmaceuticals Inc (MRNS) Wins a Bull Thanks to Potential in Multiple Central Nervous System Indications

Mizuho’s Difei Yang approaches the biotech player as a new bull, angling for a whopping 204% in return potential for MRNS shares.

NVIDIA Corporation (NVDA) Prospects Draw an Even Higher Price Target

RBC Capital’s Mitch Steves now spotlights 14% in return potential for NVDA shares.

Nutanix Inc (NTNX) Wins Another Price Target Boost

Yet another analyst has weighed in on Nutanix Inc (NASDAQ:NTNX) and pushed sales forecast higher for the hyper-converged …

New Bull Anticipates Nutanix Inc (NTNX) Set to Keep Outclassing the Market This Year

BTIG’s Edward Parker does not want to miss out any more on NTNX’s rapid-fire momentum, opting to join the bullish camp.